Inhibition of Transcription by Platinum Antitumor Compounds

Overview

Journal Metallomics

Publisher Oxford University Press

Date 2010 Jan 5

PMID 20046924

Citations 152

Authors

Ryan C Todd

Stephen J Lippard

Affiliations

Soon will be listed here.

Abstract

Cisplatin, carboplatin, and oxaliplatin are three FDA-approved members of the platinum anticancer drug family. These compounds induce apoptosis in tumor cells by binding to nuclear DNA, forming a variety of structural adducts and triggering cellular responses, one of which is the inhibition of transcription. In this report we present (i) a detailed review of the structural investigations of various Pt-DNA adducts and the effects of these lesions on global DNA geometry; (ii) research detailing inhibition of cellular transcription by Pt-DNA adducts; and (iii) a mechanistic analysis of how DNA structural distortions induced by platinum damage may inhibit RNA synthesis in vivo. A thorough understanding of the molecular mechanism of action of platinum antitumor agents will aid in the development of new compounds in the family.

Citing Articles

DEWNA: dynamic entropy weight network analysis and its application to the DNA-binding proteome in A549 cells with cisplatin-induced damage.

Wang S, Zeng W, Yang Y, Cheng J, Liu D, Yang H Brief Bioinform. 2024; 25(6).

PMID: 39487085 PMC: 11530294. DOI: 10.1093/bib/bbae564.

The unique Pt(II)-induced nucleolar stress response and its deviation from DNA damage response pathways.

Pigg H, Alley K, Griffin C, Moon C, Kraske S, DeRose V J Biol Chem. 2024; 300(11):107858.

PMID: 39374783 PMC: 11612370. DOI: 10.1016/j.jbc.2024.107858.

Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin.

Jogadi W, Kshetri M, Alqarni S, Sharma A, Cheline M, Al Amin M Molecules. 2024; 29(17).

PMID: 39274943 PMC: 11397443. DOI: 10.3390/molecules29174095.

Biological Evaluation of Dinuclear Platinum(II) Complexes with Aromatic -Heterocycles as Bridging Ligands.

Lukovic D, Franich A, Zivkovic M, Rajkovic S, Stojanovic B, Gajovic N Int J Mol Sci. 2024; 25(15).

PMID: 39126093 PMC: 11312983. DOI: 10.3390/ijms25158525.

Interactions with DNA Models of the Oxaliplatin Analog (-1,3-DACH)PtCl.

Barbanente A, Papadia P, Di Cosola A, Pacifico C, Natile G, Hoeschele J Int J Mol Sci. 2024; 25(13).

PMID: 39000496 PMC: 11242235. DOI: 10.3390/ijms25137392.

References

Lemaire M, Schwartz A, Rahmouni A, Leng M . Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. Proc Natl Acad Sci U S A. 1991; 88(5):1982-5. PMC: 51150. DOI: 10.1073/pnas.88.5.1982. View

Treiber D, Zhai X, Jantzen H, Essigmann J . Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci U S A. 1994; 91(12):5672-6. PMC: 44058. DOI: 10.1073/pnas.91.12.5672. View

Rice J, Gerberich J, Nowotnik D, Howell S . Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res. 2006; 12(7 Pt 1):2248-54. DOI: 10.1158/1078-0432.CCR-05-2169. View

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

Wu Y, Bhattacharyya D, King C, Baskerville-Abraham I, Huh S, Boysen G . Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry. 2007; 46(22):6477-87. PMC: 2129171. DOI: 10.1021/bi062291f. View

Takahara P, Rosenzweig A, Frederick C, Lippard S . Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature. 1995; 377(6550):649-52. DOI: 10.1038/377649a0. View

van Garderen C, van Houte L . The solution structure of a DNA duplex containing the cis-Pt(NH3)2[d(-GTG-)-N7(G),N7(G)] adduct, as determined with high-field NMR and molecular mechanics/dynamics. Eur J Biochem. 1994; 225(3):1169-79. View

Shapiro G, Koestner D, Matranga C, Rollins B . Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res. 1999; 5(10):2925-38. View

Holzer A, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R . The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004; 66(4):817-23. DOI: 10.1124/mol.104.001198. View

10.

Furuta T, Ueda T, Aune G, Sarasin A, Kraemer K, Pommier Y . Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002; 62(17):4899-902. View

11.

Marchenko N, Zaika A, Moll U . Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem. 2000; 275(21):16202-12. DOI: 10.1074/jbc.275.21.16202. View

12.

Wu Y, Pradhan P, Havener J, Boysen G, Swenberg J, Campbell S . NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J Mol Biol. 2004; 341(5):1251-69. DOI: 10.1016/j.jmb.2004.06.066. View

13.

Tornaletti S, Patrick S, Turchi J, Hanawalt P . Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA. J Biol Chem. 2003; 278(37):35791-7. DOI: 10.1074/jbc.M305394200. View

14.

Tremeau-Bravard A, Riedl T, Egly J, Dahmus M . Fate of RNA polymerase II stalled at a cisplatin lesion. J Biol Chem. 2003; 279(9):7751-9. DOI: 10.1074/jbc.M309853200. View

15.

Zhang S, Lovejoy K, Shima J, Lagpacan L, Shu Y, Lapuk A . Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006; 66(17):8847-57. PMC: 2775093. DOI: 10.1158/0008-5472.CAN-06-0769. View

16.

Coste F, Malinge J, Serre L, Shepard W, Roth M, Leng M . Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site. Nucleic Acids Res. 1999; 27(8):1837-46. PMC: 148391. DOI: 10.1093/nar/27.8.1837. View

17.

Ohga T, Koike K, Ono M, Makino Y, ITAGAKI Y, Tanimoto M . Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 1996; 56(18):4224-8. View

18.

Bruhn S, Pil P, Essigmann J, Housman D, Lippard S . Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci U S A. 1992; 89(6):2307-11. PMC: 48646. DOI: 10.1073/pnas.89.6.2307. View

19.

Gottesfeld J, Melander C, Suto R, Raviol H, Luger K, Dervan P . Sequence-specific recognition of DNA in the nucleosome by pyrrole-imidazole polyamides. J Mol Biol. 2001; 309(3):615-29. DOI: 10.1006/jmbi.2001.4694. View

20.

Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M . p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem. 2002; 277(35):31694-702. DOI: 10.1074/jbc.M200266200. View